Targeting CYP4A attenuates hepatic steatosis in a novel multicellular organotypic liver model

Cited 3 time in scopus
Metadata Downloads
Title
Targeting CYP4A attenuates hepatic steatosis in a novel multicellular organotypic liver model
Author(s)
Jae Sung Ryu; M Lee; Seon Ju Mun; S H Hong; Ho-Joon Lee; Hyo Suk Ahn; Kyung-Sook Chung; G H Kim; Myung Jin Son
Bibliographic Citation
Journal of Biological Engineering, vol. 13, pp. 69-69
Publication Year
2019
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) begins as simple hepatic steatosis, but further progress to chronic liver diseases results in severe liver damage and hepatic failure. However, therapeutic options are scarce due to the lack of reliable human in vitro liver models for understanding disease progression mechanisms and developing therapies. RESULTS: We describe here a novel method for generating 3D hepatic spheroids using HepaRG cells, vascular endothelial cells, and mesenchymal stem cells cultured on a thick layer of soft matrix in a narrow conical tube; this method improved self-organization efficiency and functional competence. We further developed a 3D hepatic steatosis model with excess glucose and palmitate, accurately recapitulating steatosis phenotypes such as neutral lipid accumulation, enhanced expression of lipogenesis and gluconeogenesis markers, increased intracellular triglyceride content, and reduced glucose uptake. The expression and activity of cytochrome P450 4A (CYP4A), a hepatic glucose and lipid homeostasis enzyme, that is highly expressed in liver tissues from NAFLD patients, was induced in our in vitro steatosis model, and inhibiting CYP4A with the selective inhibitor HET0016 or a specific siRNA ameliorated steatosis-related pathology through reduced ER stress and improved insulin signaling. CONCLUSIONS: We provide here a novel 3D human cell-based hepatic model that can be easily generated and reliably simulate hepatic steatosis pathology. We have experimentally validated its potential for target validation and drug evaluation by focusing on CYP4A, which may serve as a translational platform for drug development.
Keyword
3DCYP4AHET0016Hepatic steatosisLiver
ISSN
1754-1611
Publisher
Springer-BMC
DOI
http://dx.doi.org/10.1186/s13036-019-0198-8
Type
Article
Appears in Collections:
Division of Research on National Challenges > 1. Journal Articles
Division of Research on National Challenges > Stem Cell Convergenece Research Center > 1. Journal Articles
Files in This Item:

Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.